PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29521222-4 2017 RESULTS: We observed that quinidine, a substrate for MDR1 transporter, showed efflux ratio (Papp B-A/ Papp A-B) of 838 in MDCKII-MDR1 cells which plummeted to 14 in presence of verapamil, a known inhibitor of MDR1. Quinidine 26-35 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 29521222-4 2017 RESULTS: We observed that quinidine, a substrate for MDR1 transporter, showed efflux ratio (Papp B-A/ Papp A-B) of 838 in MDCKII-MDR1 cells which plummeted to 14 in presence of verapamil, a known inhibitor of MDR1. Quinidine 26-35 ATP binding cassette subfamily B member 1 Homo sapiens 129-133 29521222-4 2017 RESULTS: We observed that quinidine, a substrate for MDR1 transporter, showed efflux ratio (Papp B-A/ Papp A-B) of 838 in MDCKII-MDR1 cells which plummeted to 14 in presence of verapamil, a known inhibitor of MDR1. Quinidine 26-35 ATP binding cassette subfamily B member 1 Homo sapiens 129-133 27652191-3 2016 In this study, we have evaluated the inhibitory effects of natural bioflavonoids (quercetin and silymarin) on P-gp by using digoxin and quinidine as model P-gp model substrate drugs. Quinidine 136-145 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 27262425-0 2016 Structure-activity relationships of dibenzoylhydrazines for the inhibition of P-glycoprotein-mediated quinidine transport. Quinidine 102-111 ATP binding cassette subfamily B member 1 Homo sapiens 78-92 27262425-2 2016 In the present study, we evaluated the inhibition of P-gp-mediated quinidine transport by two series of DBHs and performed a classical QSAR analysis and docking simulation in order to investigate the mechanisms underlying P-gp substrate/inhibitor recognition. Quinidine 67-76 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 27262425-2 2016 In the present study, we evaluated the inhibition of P-gp-mediated quinidine transport by two series of DBHs and performed a classical QSAR analysis and docking simulation in order to investigate the mechanisms underlying P-gp substrate/inhibitor recognition. Quinidine 67-76 ATP binding cassette subfamily B member 1 Homo sapiens 222-226 25168620-7 2014 With IV dosing of edoxaban, co-administration of the P-gp inhibitor quinidine decreased both edoxaban clearance (CL) and V 2, resulting in an increase of 32 % in AUC and 66 % in C 24. Quinidine 68-77 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 26995013-8 2016 We also examined the inhibitory effects of DBHs on quinidine (a P-gp substrate) transport by P-gp in order to ascertain whether these derivatives are inhibitors of P-gp. Quinidine 51-60 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 26995013-8 2016 We also examined the inhibitory effects of DBHs on quinidine (a P-gp substrate) transport by P-gp in order to ascertain whether these derivatives are inhibitors of P-gp. Quinidine 51-60 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 26995013-8 2016 We also examined the inhibitory effects of DBHs on quinidine (a P-gp substrate) transport by P-gp in order to ascertain whether these derivatives are inhibitors of P-gp. Quinidine 51-60 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 25901027-7 2015 Furthermore, the intestinal absorption of P-gp substrates (quinidine and etoposide) was substantially suppressed by administering the drugs at the times of day when P-gp levels were abundant. Quinidine 59-68 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 25901027-7 2015 Furthermore, the intestinal absorption of P-gp substrates (quinidine and etoposide) was substantially suppressed by administering the drugs at the times of day when P-gp levels were abundant. Quinidine 59-68 ATP binding cassette subfamily B member 1 Homo sapiens 165-169 26248047-0 2016 The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol. Quinidine 14-23 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 26248047-3 2016 This double-blind, randomized, 2-part, crossover study in healthy volunteers evaluated the effect of quinidine (600 mg PO), a CYP3A/PGP transporter inhibitor, on the pharmacokinetics and CNS distribution of naloxegol (25 mg PO). Quinidine 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 132-135 26248047-5 2016 Coadministration of quinidine and naloxegol increased naloxegol"s AUC 1.4-fold and Cmax 2.5-fold but did not antagonize morphine-induced miosis, suggesting that PGP inhibition does not increase the CNS penetration of naloxegol. Quinidine 20-29 ATP binding cassette subfamily B member 1 Homo sapiens 161-164 20135207-4 2010 METHODS: The previously reported concentration-dependent permeability of verapamil, quinidine, and vinblastine in MDR1-MDCKII, P-gp-highly induced Caco-2, P-gp-induced Caco-2, normal Caco-2, and MDR1-knockdown Caco-2 cells data were analyzed using a model in which the Km value was defined for the intracellular substrate concentration. Quinidine 84-93 ATP binding cassette subfamily B member 1 Homo sapiens 114-118 23435914-4 2013 Compared with MDCKII or MCF-7, intracellular distribution of [(3)H]-menadione was significantly lower in MDCKII/MDR1 or NCI/ADR-RES cells, which could be restored by the P-gp inhibitors, verapamil and quinidine. Quinidine 201-210 ATP binding cassette subfamily B member 1 Homo sapiens 170-174 21716273-3 2011 Verapamil and quinidine are good substrates of both the multidrug resistance 1 transporter (MDR1) and the cytochrome P450 (CYP) 3A4 enzyme (CYP3A4). Quinidine 14-23 ATP binding cassette subfamily B member 1 Homo sapiens 56-78 21716273-3 2011 Verapamil and quinidine are good substrates of both the multidrug resistance 1 transporter (MDR1) and the cytochrome P450 (CYP) 3A4 enzyme (CYP3A4). Quinidine 14-23 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 21484807-5 2011 The inhibition of P-gp-mediated efflux of these two fluorescent substrates by several drugs, including quinidine and itraconazole, was found to be substrate- and/or species-dependent. Quinidine 103-112 ATP binding cassette subfamily B member 1 Homo sapiens 18-22 19816852-0 2010 Development and validation of RP-HPLC-fluorescence method for quantitative determination of quinidine, a probe substrate for P-glycoprotein inhibition assay using Caco-2 cell monolayer. Quinidine 92-101 ATP binding cassette subfamily B member 1 Homo sapiens 125-139 19816852-2 2010 The method was applicable in the bi-directional transport assay for evaluation of the inhibitory effect of test compounds on P-glycoprotein-mediated quinidine transport; quinidine was used as a probe P-glycoprotein substrate. Quinidine 149-158 ATP binding cassette subfamily B member 1 Homo sapiens 125-139 19816852-2 2010 The method was applicable in the bi-directional transport assay for evaluation of the inhibitory effect of test compounds on P-glycoprotein-mediated quinidine transport; quinidine was used as a probe P-glycoprotein substrate. Quinidine 170-179 ATP binding cassette subfamily B member 1 Homo sapiens 125-139 19816852-2 2010 The method was applicable in the bi-directional transport assay for evaluation of the inhibitory effect of test compounds on P-glycoprotein-mediated quinidine transport; quinidine was used as a probe P-glycoprotein substrate. Quinidine 170-179 ATP binding cassette subfamily B member 1 Homo sapiens 200-214 20163161-5 2010 In this study, the effects of the aqueous boundary layers, extracellular pH and cellular retention on the apparent saturation kinetics of P-glycoprotein mediated transport of quinidine in an in vitro cell permeation setting were explored. Quinidine 175-184 ATP binding cassette subfamily B member 1 Homo sapiens 138-152 20163161-6 2010 The changes in the experimental conditions caused 1 order of magnitude variation in the apparent affinity to P-glycoprotein (K(m,app)) and a 5-fold difference in the maximum effective P-glycoprotein mediated transport rate of quinidine (V(max,app)). Quinidine 226-235 ATP binding cassette subfamily B member 1 Homo sapiens 109-123 20163161-6 2010 The changes in the experimental conditions caused 1 order of magnitude variation in the apparent affinity to P-glycoprotein (K(m,app)) and a 5-fold difference in the maximum effective P-glycoprotein mediated transport rate of quinidine (V(max,app)). Quinidine 226-235 ATP binding cassette subfamily B member 1 Homo sapiens 184-198 20214407-4 2010 Digoxin, fexofenadine, talinolol and quinidine are commonly used probe drugs for P-gp phenotyping. Quinidine 37-46 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 24212378-4 2014 From a set of potential P-gp inhibitors, clarithromycin, cyclosporin A, itraconazole, ketoconazole, quinidine, and ritonavir inhibited P-gp-mediated transport of dabigatran etexilate over a concentration range that may hypothetically occur in the intestine. Quinidine 100-109 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 24212378-4 2014 From a set of potential P-gp inhibitors, clarithromycin, cyclosporin A, itraconazole, ketoconazole, quinidine, and ritonavir inhibited P-gp-mediated transport of dabigatran etexilate over a concentration range that may hypothetically occur in the intestine. Quinidine 100-109 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 23784266-11 2013 CONCLUSION: Coadministration of the P-gp inhibitors quinidine, verapamil, and dronedarone increased edoxaban exposure. Quinidine 52-61 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 20135207-4 2010 METHODS: The previously reported concentration-dependent permeability of verapamil, quinidine, and vinblastine in MDR1-MDCKII, P-gp-highly induced Caco-2, P-gp-induced Caco-2, normal Caco-2, and MDR1-knockdown Caco-2 cells data were analyzed using a model in which the Km value was defined for the intracellular substrate concentration. Quinidine 84-93 ATP binding cassette subfamily B member 1 Homo sapiens 127-131 20135207-4 2010 METHODS: The previously reported concentration-dependent permeability of verapamil, quinidine, and vinblastine in MDR1-MDCKII, P-gp-highly induced Caco-2, P-gp-induced Caco-2, normal Caco-2, and MDR1-knockdown Caco-2 cells data were analyzed using a model in which the Km value was defined for the intracellular substrate concentration. Quinidine 84-93 ATP binding cassette subfamily B member 1 Homo sapiens 155-159 20135207-4 2010 METHODS: The previously reported concentration-dependent permeability of verapamil, quinidine, and vinblastine in MDR1-MDCKII, P-gp-highly induced Caco-2, P-gp-induced Caco-2, normal Caco-2, and MDR1-knockdown Caco-2 cells data were analyzed using a model in which the Km value was defined for the intracellular substrate concentration. Quinidine 84-93 ATP binding cassette subfamily B member 1 Homo sapiens 195-199 18718123-4 2008 Treatment with transporter inhibitors MK571, quinidine or mitoxantrone, which inhibit MRP2, P-glycoprotein (P-gp) and BCRP, respectively, led to an increase in the accumulation of EC into Caco-2 cells and a decrease in the Papp ratio (Papp B-->A/Papp A-->B) for EC. Quinidine 45-54 ATP binding cassette subfamily B member 1 Homo sapiens 92-106 19631272-5 2010 Quinidine and verapamil, known MDR1 substrates/inhibitors, showed trans-inhibition on MDR1-mediated [(3)H]vinblastine and [(3)H]digoxin efflux. Quinidine 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 19631272-5 2010 Quinidine and verapamil, known MDR1 substrates/inhibitors, showed trans-inhibition on MDR1-mediated [(3)H]vinblastine and [(3)H]digoxin efflux. Quinidine 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 18945821-2 2009 In this work, rationally designed second-generation P-gp inhibitors are disclosed, based on dimerized versions of the substrates quinine and quinidine. Quinidine 141-150 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 18703021-7 2008 A number of Pgp substrates (quinidine, amprenavir, irinotecan, topotecan, atorvastatin and erythromycin) induced net digoxin secretion, as did the non-Pgp substrate artemisinin. Quinidine 28-37 ATP binding cassette subfamily B member 1 Homo sapiens 12-15 18703021-9 2008 Of the compounds that increased Pgp secretion, quinidine, topotecan, atorvastatin and amprenavir pre-exposure also elevated MDR1 mRNA levels, whereas erythromycin, irinotecan and artemisinin displayed no change in transcript levels. Quinidine 47-56 ATP binding cassette subfamily B member 1 Homo sapiens 124-128 19122284-6 2009 Upon addition of quinidine, a mixed P-gp and MRP1 inhibitor, the permeation of W2 from the apical side was significantly increased (P(app) 17.1+/-0.32x10(-6) cm/s) while the efflux was inhibited (P(app) 21.3+/-0.19x10(-6) cm/s). Quinidine 17-26 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 18718123-4 2008 Treatment with transporter inhibitors MK571, quinidine or mitoxantrone, which inhibit MRP2, P-glycoprotein (P-gp) and BCRP, respectively, led to an increase in the accumulation of EC into Caco-2 cells and a decrease in the Papp ratio (Papp B-->A/Papp A-->B) for EC. Quinidine 45-54 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 18668443-9 2008 Additionally, the low IC(50) values determined for ketoconazole and quinidine indicated that these inhibitors were suitable to use to confirm the role of P-gp in the efflux of a test compound. Quinidine 68-77 ATP binding cassette subfamily B member 1 Homo sapiens 154-158 18057117-6 2008 Using this assay, quinine, quinidine, CsA, and amprenavir were predicted to be the most potent P-gp inhibitors in vivo at their respective therapeutic maximal unbound plasma concentrations. Quinidine 27-36 ATP binding cassette subfamily B member 1 Homo sapiens 95-99 17094122-3 2007 The purpose of the present study was to evaluate the species differences in the inhibitory effects of typical P-gp inhibitors, quinidine and verapamil, on P-gp-mediated drug transport using MDR1 transfected cell lines. Quinidine 127-136 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 17548462-6 2007 The effect of increasing P-glycoprotein expression on apparent transport kinetics was studied using quinidine and digoxin as model compounds. Quinidine 100-109 ATP binding cassette subfamily B member 1 Homo sapiens 25-39 17094122-5 2007 On daunorubicin transport, the relative IC(50) value (quinidine IC(50)/verapamil IC(50)) of human P-gp was 5.25 and those from other species ranged from 0.89 to 10.70. Quinidine 54-63 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 17967933-3 2008 Using a confluent monolayer of MDCKII-hMDR1 cells, we have determined the elementary rate constants for the P-gp efflux of amprenavir, digoxin, loperamide, and quinidine. Quinidine 160-169 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 17967933-4 2008 For amprenavir and quinidine, transport was fitted with just P-gp and passive permeability. Quinidine 19-28 ATP binding cassette subfamily B member 1 Homo sapiens 61-65 17967933-8 2008 We propose that amprenavir and quinidine are robust probe substrates for assessing P-gp interactions using the MDCKII-hMDR1 confluent cell monolayer. Quinidine 31-40 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 17967933-8 2008 We propose that amprenavir and quinidine are robust probe substrates for assessing P-gp interactions using the MDCKII-hMDR1 confluent cell monolayer. Quinidine 31-40 ATP binding cassette subfamily B member 1 Homo sapiens 118-123 17094122-3 2007 The purpose of the present study was to evaluate the species differences in the inhibitory effects of typical P-gp inhibitors, quinidine and verapamil, on P-gp-mediated drug transport using MDR1 transfected cell lines. Quinidine 127-136 ATP binding cassette subfamily B member 1 Homo sapiens 155-159 17094122-3 2007 The purpose of the present study was to evaluate the species differences in the inhibitory effects of typical P-gp inhibitors, quinidine and verapamil, on P-gp-mediated drug transport using MDR1 transfected cell lines. Quinidine 127-136 ATP binding cassette subfamily B member 1 Homo sapiens 190-194 15229466-10 2004 Its extent is considerable and similar to the effect of other potent P-gp inhibitors on digoxin disposition such as quinidine. Quinidine 116-125 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 17713975-2 2007 We therefore investigated whether inhibition of intestinal P-glycoprotein-mediated efflux by quinidine leads to increased absorption of the P-glycoprotein substrate digoxin. Quinidine 93-102 ATP binding cassette subfamily B member 1 Homo sapiens 59-73 17713975-2 2007 We therefore investigated whether inhibition of intestinal P-glycoprotein-mediated efflux by quinidine leads to increased absorption of the P-glycoprotein substrate digoxin. Quinidine 93-102 ATP binding cassette subfamily B member 1 Homo sapiens 140-154 17713975-6 2007 One of the segments was additionally perfused with the P-glycoprotein inhibitor quinidine. Quinidine 80-89 ATP binding cassette subfamily B member 1 Homo sapiens 55-69 16647797-6 2006 Treatment with quinidine or cyclosporine A, which are P-gp inhibitors, decreased the P(app) of Rho-123 to the same degree in both monolayers. Quinidine 15-24 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 16406207-5 2006 The inhibitory potencies (apparent IC50) of known Pgp inhibitors astemizole, GF120918, ketoconazole, itraconazole, quinidine, verapamil and quinine were determined over at least a 1000-fold concentration range. Quinidine 115-124 ATP binding cassette subfamily B member 1 Homo sapiens 50-53 12621387-8 2003 Enterocyte P-glycoprotein content correlated with the area under the plasma concentration-time curve of digoxin (Spearman nonparametric correlation coefficient [r(S)] = -0.73, P =.003) and digoxin nonrenal clearance (r(S) = 0.52, P =.056), as well as with intraluminal and plasma concentrations of quinidine (r(S) = 0.55, P =.041 and r(S) = -0.67, P =.009, respectively). Quinidine 298-307 ATP binding cassette subfamily B member 1 Homo sapiens 11-25 15981588-0 2004 Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization. Quinidine 57-66 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 15981588-1 2004 The objective of this study is to investigate whether transporter-targeted prodrug derivatization of quinidine, a model P-glycoprotein (P-gp) substrate, can circumvent P-gp-mediated efflux. Quinidine 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 120-134 15981588-1 2004 The objective of this study is to investigate whether transporter-targeted prodrug derivatization of quinidine, a model P-glycoprotein (P-gp) substrate, can circumvent P-gp-mediated efflux. Quinidine 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 136-140 15981588-1 2004 The objective of this study is to investigate whether transporter-targeted prodrug derivatization of quinidine, a model P-glycoprotein (P-gp) substrate, can circumvent P-gp-mediated efflux. Quinidine 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 168-172 15981588-10 2004 Results from this study clearly indicate that prodrug derivatization of quinidine into val-quinidine can overcome P-gp-mediated efflux. Quinidine 72-81 ATP binding cassette subfamily B member 1 Homo sapiens 114-118 14973303-0 2004 Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. Quinidine 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 37-51 14973303-12 2004 Quinidine increased oral fentanyl plasma concentrations, suggesting that intestinal P-gp or some other quinidine-sensitive transporter affects the absorption, bioavailability, and hence clinical effects of oral fentanyl. Quinidine 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 14973303-13 2004 Quinidine had less effect on fentanyl pharmacodynamics, suggesting that if quinidine is an effective inhibitor of brain P-gp, then P-gp appears to have less effect on brain access of fentanyl. Quinidine 75-84 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 12948018-11 2003 For structurally diverse P-gp substrates (acebutolol, colchicine, digoxin, etoposide, methylprednisolone, prednisolone, quinidine, and talinolol) apparent Km was approximately 3 to 8-fold greater in absorptive vs. secretory transport direction, whereas apparent J(max) was somewhat similar in both transport directions. Quinidine 120-129 ATP binding cassette subfamily B member 1 Homo sapiens 25-29 15089813-13 2004 CONCLUSIONS: Quinidine increased the plasma concentrations of oral methadone in the absorptive phase and the miosis caused by methadone, suggesting that intestinal P-gp affects oral methadone absorption and hence its clinical effects. Quinidine 13-22 ATP binding cassette subfamily B member 1 Homo sapiens 164-168 14663457-18 2003 DISCUSSION: Quinidine increased the absorption and plasma concentrations of oral morphine, suggesting that intestinal P-glycoprotein affected the absorption, bioavailability, and, hence, clinical effects of oral morphine. Quinidine 12-21 ATP binding cassette subfamily B member 1 Homo sapiens 118-132 14583678-10 2003 The ABCB1 TT3435 genotype was associated with the most pronounced increase of the miotic effects of loperamide when quinidine was co-administered. Quinidine 116-125 ATP binding cassette subfamily B member 1 Homo sapiens 4-9 14534517-0 2003 Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Quinidine 99-108 ATP binding cassette subfamily B member 1 Homo sapiens 70-84 14534517-1 2003 AIM: Our objective was to evaluate whether P-glycoprotein inhibition after quinidine pretreatment results in modified central nervous effects of morphine. Quinidine 75-84 ATP binding cassette subfamily B member 1 Homo sapiens 43-57 14534517-11 2003 CONCLUSIONS: Whereas morphine clearly produced miosis and respiratory depression, pretreatment with quinidine as an inhibitor of P-glycoprotein did not result in an enhancement of central nervous opioid effects in healthy volunteers. Quinidine 100-109 ATP binding cassette subfamily B member 1 Homo sapiens 129-143 12948010-6 2003 Furthermore, a mixture of pH-dependent passive and active efflux was found for the P-glycoprotein (P-gp, MDR1, ABCB1) substrates, talinolol and quinidine, but not for the neutral drug, digoxin. Quinidine 144-153 ATP binding cassette subfamily B member 1 Homo sapiens 83-97 12948010-8 2003 Hence, the degree of interaction depends on the amount of quinidine available at the binding site of the P-gp. Quinidine 58-67 ATP binding cassette subfamily B member 1 Homo sapiens 105-109 12948013-5 2003 RESULTS: In situ experimental results revealed that the extent to which the intestinal absorption is affected by P-gp was in the following order: quinidine > ritonavir > loperamide, verapamil, daunomycin > digoxin, cyclosporin A > dexamethasone, and vinblastine. Quinidine 146-155 ATP binding cassette subfamily B member 1 Homo sapiens 113-117 12649369-5 2003 All antidepressants tested except O-desmethylvenlafaxine showed Pgp inhibitory activity with sertraline, desmethylsertraline, and paroxetine being the most potent, comparable with the well known Pgp inhibitor quinidine. Quinidine 209-218 ATP binding cassette subfamily B member 1 Homo sapiens 195-198 11821009-6 2002 Pretreatment of the BBB model with the P-gp inhibitor, quinidine, significantly increased apical to basal transport. Quinidine 55-64 ATP binding cassette subfamily B member 1 Homo sapiens 39-43 11336351-6 2001 The potency of inhibition of P-gp was cyclosporine > tacrolimus > quinidine > verapamil > vinblastine. Quinidine 72-81 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 11821009-9 2002 Moreover, the activation of P-gp ATPase by indinavir was inhibited by quinidine. Quinidine 70-79 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 11504821-8 2001 The efflux of etoposide, a known substrate for both Pgp and MRP1, was shown to be mainly Pgp-mediated by using the multidrug-resistant inhibitors quinidine (mixed Pgp/MRP1), CsA (Pgp), and MK571 (MRP1). Quinidine 146-155 ATP binding cassette subfamily B member 1 Homo sapiens 52-55 11504821-8 2001 The efflux of etoposide, a known substrate for both Pgp and MRP1, was shown to be mainly Pgp-mediated by using the multidrug-resistant inhibitors quinidine (mixed Pgp/MRP1), CsA (Pgp), and MK571 (MRP1). Quinidine 146-155 ATP binding cassette subfamily B member 1 Homo sapiens 89-92 11504821-8 2001 The efflux of etoposide, a known substrate for both Pgp and MRP1, was shown to be mainly Pgp-mediated by using the multidrug-resistant inhibitors quinidine (mixed Pgp/MRP1), CsA (Pgp), and MK571 (MRP1). Quinidine 146-155 ATP binding cassette subfamily B member 1 Homo sapiens 89-92 11504821-8 2001 The efflux of etoposide, a known substrate for both Pgp and MRP1, was shown to be mainly Pgp-mediated by using the multidrug-resistant inhibitors quinidine (mixed Pgp/MRP1), CsA (Pgp), and MK571 (MRP1). Quinidine 146-155 ATP binding cassette subfamily B member 1 Homo sapiens 89-92 11356921-4 2001 Fluorescein/probenecid and quinidine/LY-335979 were chosen as the substrate/inhibitor combinations for organic anion transport and P-glycoprotein-medicated transport, respectively. Quinidine 27-36 ATP binding cassette subfamily B member 1 Homo sapiens 131-145 10772630-5 2000 Known Pgp inhibitors, such as cyclosporin A, nicardipine, verapamil, quinidine, terfenadine, tamoxifen, and vinblastine were demonstrated to inhibit the Pgp-mediated efflux of daunorubicin. Quinidine 69-78 ATP binding cassette subfamily B member 1 Homo sapiens 6-9 10772630-5 2000 Known Pgp inhibitors, such as cyclosporin A, nicardipine, verapamil, quinidine, terfenadine, tamoxifen, and vinblastine were demonstrated to inhibit the Pgp-mediated efflux of daunorubicin. Quinidine 69-78 ATP binding cassette subfamily B member 1 Homo sapiens 153-156 9482283-9 1998 When MCS were incubated with verapamil, cyclosporin A, orthovanadate, and quinidine, which are known to reverse P-glycoprotein (Pgp)-mediated multidrug resistance (MDR), Dox accumulated also in deeper cell layers. Quinidine 74-83 ATP binding cassette subfamily B member 1 Homo sapiens 112-126 10838122-3 2000 Results showed that the accumulation of P-gp substrates calcein-AM and vinblastine by BeWo cells or primary cultures of human cytotrophoblasts was significantly enhanced in the presence of a typical P-gp inhibitor, cyclosporin-A, or other inhibitors such as quinidine, verapamil, and dipyridamole. Quinidine 258-267 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 10838122-3 2000 Results showed that the accumulation of P-gp substrates calcein-AM and vinblastine by BeWo cells or primary cultures of human cytotrophoblasts was significantly enhanced in the presence of a typical P-gp inhibitor, cyclosporin-A, or other inhibitors such as quinidine, verapamil, and dipyridamole. Quinidine 258-267 ATP binding cassette subfamily B member 1 Homo sapiens 199-203 9506530-6 1998 The P-glycoprotein-mediated multidrug resistance (MDR)-reversing agents verapamil, cyclosporin A, quinidine, sodium orthovanadate and tamoxifen significantly increased dox fluorescence at this depth, whereas genistein, indomethacin, probenecid and brefeldin A, which reverse multidrug-resistance-associated protein (MRP) function, exerted no effect. Quinidine 98-107 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 9528676-3 1998 The cardioactive drugs verapamil, quinidine, diltiazem, nifedipine, and a series of digitalis analogs, interacted directly with Pgp as shown on ATPase in both systems. Quinidine 34-43 ATP binding cassette subfamily B member 1 Homo sapiens 128-131 10706193-5 2000 Human P-glycoprotein has been shown to transport a wide range of structurally unrelated drugs such as digoxin, quinidine, cyclosporine and HIV-1 protease inhibitors. Quinidine 111-120 ATP binding cassette subfamily B member 1 Homo sapiens 6-20 10706193-7 2000 Moreover, P-glycoprotein knock-out mice were used to identify inhibition of P-glycoprotein-mediated transport as a mechanism for drug interactions such as the digoxin-quinidine interaction. Quinidine 167-176 ATP binding cassette subfamily B member 1 Homo sapiens 10-24 10706193-7 2000 Moreover, P-glycoprotein knock-out mice were used to identify inhibition of P-glycoprotein-mediated transport as a mechanism for drug interactions such as the digoxin-quinidine interaction. Quinidine 167-176 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 9482283-9 1998 When MCS were incubated with verapamil, cyclosporin A, orthovanadate, and quinidine, which are known to reverse P-glycoprotein (Pgp)-mediated multidrug resistance (MDR), Dox accumulated also in deeper cell layers. Quinidine 74-83 ATP binding cassette subfamily B member 1 Homo sapiens 128-131 9235086-9 1997 Chemicals such as verapamil, nifedine, quinidine and calmodulin inhibitors are joined to pgp inhibiting it. Quinidine 39-48 ATP binding cassette subfamily B member 1 Homo sapiens 89-92 9488065-11 1998 Calcium-channel blockers (verapamil, quinidine) and protein kinase C inhibitors (tamoxifen) inhibited gp-170 activity and slowed the drug-efflux pump, with the acquired-MDR cells subsequently accumulating anticancer drugs. Quinidine 37-46 ATP binding cassette subfamily B member 1 Homo sapiens 102-108 7643631-4 1995 Downmodulation of Pgp function in these cell lines could be demonstrated with different substances (verapamil, vinblastine, trifluoperazine, cyclosporin A, progesterone and quinidine) and was proven to be consistently higher in the vinblastine selected cells than in their non-selected drug sensitive counterparts. Quinidine 173-182 ATP binding cassette subfamily B member 1 Homo sapiens 18-21 7547962-7 1995 P-glycoprotein modulators generally demonstrated significantly greater potency (EC50; microM): SDZ PSC 833, 0.08; cyclosporin A, 1.3; verapamil, 4.1; quinidine, 6.4; prazosin, > 300. Quinidine 150-159 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 7547962-10 1995 Scatchard analysis showed quinidine to be a noncompetitive inhibitor of P-glycoprotein-mediated Tc-SESTAMIBI transport, indicating allosteric effector sites on P-glycoprotein. Quinidine 26-35 ATP binding cassette subfamily B member 1 Homo sapiens 72-86 7547962-10 1995 Scatchard analysis showed quinidine to be a noncompetitive inhibitor of P-glycoprotein-mediated Tc-SESTAMIBI transport, indicating allosteric effector sites on P-glycoprotein. Quinidine 26-35 ATP binding cassette subfamily B member 1 Homo sapiens 160-174 7808368-4 1994 The existence of drugs (calcium blockers, cyclosporine, tamoxifen, reserpine, quinidine) able to bind themselves to gp170 and to paralyze its activity in vitro is well known. Quinidine 78-87 ATP binding cassette subfamily B member 1 Homo sapiens 116-121 7931489-10 1994 In 10 of 11 samples, the multi-drug resistance (Mdr) modulator quinidine altered nuclear daunorubicin (DNR) accumulation and whole-cell TPT accumulation by less than 15%, which suggests that Pgp-mediated effects on drug efflux are insufficient to explain the fourfold range of TPT sensitivities in the colony-forming assays. Quinidine 63-72 ATP binding cassette subfamily B member 1 Homo sapiens 191-194 7747708-2 1995 Quinidine is known to inhibit p-glycoprotein and enhance the activity of vinblastine against cultured renal carcinoma cells. Quinidine 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 30-44 8083699-1 1994 PURPOSE: To evaluate the effect of quinidine, a putative modulator of P-glycoprotein-mediated drug resistance, on the response rate and toxicity profile of epirubicin in patients with advanced breast cancer. Quinidine 35-44 ATP binding cassette subfamily B member 1 Homo sapiens 70-84 7908989-11 1994 Verapamil and quinidine lowered the IC50 values of doxorubicin for MDR1-positive cell lines. Quinidine 14-23 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 7911345-11 1993 Reversal compounds specifically inhibiting Pgp were found, such as verapamil, cyclosporin or quinidine. Quinidine 93-102 ATP binding cassette subfamily B member 1 Homo sapiens 43-46 1674435-4 1991 The potential therefore exists for new therapeutic studies aimed at circumventing resistance which develops through this mechanism, by using modulators, such as verapamil, quinidine and several others, which prevent cellular drug efflux by competitive binding to P-glycoprotein. Quinidine 172-181 ATP binding cassette subfamily B member 1 Homo sapiens 263-277 8099844-5 1993 P-Glycoprotein inhibitors such as quinidine, verapamil, vincristine, and cyclosporine increased the net A-B flux and inhibited the total B-A flux without affecting the nonspecific flux significantly. Quinidine 34-43 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 1359120-2 1992 In this study, it was demonstrated that digoxin is a substrate of P-glycoprotein, and the mechanism of a clinically important drug interaction, such as digoxin-quinidine, was elucidated. Quinidine 160-169 ATP binding cassette subfamily B member 1 Homo sapiens 66-80 1359120-11 1992 These findings demonstrate that digoxin is transported by human P-glycoprotein, which is a previously undiscovered drug transport system in the kidney other than organic cation and anion transport systems, and suggest a molecular mechanism for the renal tubular secretion of digoxin as well as clinically important digoxin-quinidine interaction via P-glycoprotein. Quinidine 323-332 ATP binding cassette subfamily B member 1 Homo sapiens 64-78 1348448-9 1992 Cytotoxicity measurements performed by counting the number of surviving cells (MCF-7/Adriar) or employing a modified, highly stable tetrazolium dye reduction assay (leukemia cell lines) revealed that quinidine diminished the IC50 for TPT in the Pgp-overexpressing cell lines but not in the control lines. Quinidine 200-209 ATP binding cassette subfamily B member 1 Homo sapiens 245-248 34903589-6 2022 Reported digoxin concentrations in a drug-drug interaction study with MDR1 inhibitors quinidine and verapamil were consistent with the profiles simulated by our model incorporating inhibition of efflux transporter at the BM in addition to MVM. Quinidine 86-95 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 34668334-2 2022 This study aimed to investigate an IVIVE for intestinal P-glycoprotein (Pgp, ABCB1)-mediated DDIs between three Pgp substrates, digoxin, dabigatran etexilate and quinidine, and two Pgp inhibitors, itraconazole and verapamil, via PBPK modeling. Quinidine 162-171 ATP binding cassette subfamily B member 1 Homo sapiens 56-70 34668334-2 2022 This study aimed to investigate an IVIVE for intestinal P-glycoprotein (Pgp, ABCB1)-mediated DDIs between three Pgp substrates, digoxin, dabigatran etexilate and quinidine, and two Pgp inhibitors, itraconazole and verapamil, via PBPK modeling. Quinidine 162-171 ATP binding cassette subfamily B member 1 Homo sapiens 72-75 34668334-2 2022 This study aimed to investigate an IVIVE for intestinal P-glycoprotein (Pgp, ABCB1)-mediated DDIs between three Pgp substrates, digoxin, dabigatran etexilate and quinidine, and two Pgp inhibitors, itraconazole and verapamil, via PBPK modeling. Quinidine 162-171 ATP binding cassette subfamily B member 1 Homo sapiens 77-82 34668334-2 2022 This study aimed to investigate an IVIVE for intestinal P-glycoprotein (Pgp, ABCB1)-mediated DDIs between three Pgp substrates, digoxin, dabigatran etexilate and quinidine, and two Pgp inhibitors, itraconazole and verapamil, via PBPK modeling. Quinidine 162-171 ATP binding cassette subfamily B member 1 Homo sapiens 112-115 1967551-7 1990 Modulators of Pgp-MDR also compete with LU-49888 for binding to Pgp: verapamil (82%), diltiazem (73%), quinidine (91%), reserpine (91%), rescinnamine (88%), and trimethoxybenzoylyohimbine (89%). Quinidine 103-112 ATP binding cassette subfamily B member 1 Homo sapiens 14-17 34268580-6 2021 For digoxin, verapamil and quinidine, in vitro kinetic data on their transport by Pgp were derived from literature and used to scale to in vivo parameters. Quinidine 27-36 ATP binding cassette subfamily B member 1 Homo sapiens 82-85 35616006-7 2022 The AUC of asciminib was marginally decreased by concomitant administration with the strong CYP3A inducer rifampicin (by ~13-15%) and the strong P-gp inhibitor quinidine (by ~13-16%). Quinidine 160-169 ATP binding cassette subfamily B member 1 Homo sapiens 145-149 35570332-4 2022 The constructed rifampicin model was verified using the remaining 5 DDI cases with digoxin and 5 DDI cases with other P-gp substrates (talinolol and quinidine). Quinidine 149-158 ATP binding cassette subfamily B member 1 Homo sapiens 118-122 35570332-8 2022 For quinidine, predicted intestinal P-gp/CYP3A-mediated DDIs were slightly underestimated due to the complexity of non-linearity and transporter-enzyme interplay. Quinidine 4-13 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 34009624-3 2021 The previous UWL resistance model was well fitted to Papp of static and flow condition by assuming UWL including and negligible condition, while P-gp substrates of higher passive permeability (quinidine) was apart from the fitting curve. Quinidine 193-202 ATP binding cassette subfamily B member 1 Homo sapiens 145-149 34009624-4 2021 The concentration dependent non-linear kinetics of P-gp substrates, quinidine and talinolol, was more analyzed in detail, and apparent Vmax discrepancy between static and flow assay condition in the quinidine assay was observed, while that was not observed in talinolol, the lower permeable substrate. Quinidine 68-77 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 34009624-4 2021 The concentration dependent non-linear kinetics of P-gp substrates, quinidine and talinolol, was more analyzed in detail, and apparent Vmax discrepancy between static and flow assay condition in the quinidine assay was observed, while that was not observed in talinolol, the lower permeable substrate. Quinidine 199-208 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 2724349-0 1989 MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. Quinidine 127-136 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 2724349-6 1989 The enhancing effect of quinidine (7.5 micrograms/mL) on sensitivity to ADR was statistically significant only in the group with high MDR1 RNA levels. Quinidine 24-33 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 2724349-7 1989 Similar enhancement by quinidine of sensitivity to ADR was also observed in the established RCC cell lines in which MDR1 RNA levels were high. Quinidine 23-32 ATP binding cassette subfamily B member 1 Homo sapiens 116-120 3681376-3 1987 Two criteria suggest that primary multidrug resistance in human adenocarcinomas of the kidney results, at least in part, from expression of the mdr1 gene: (1) mdr1 mRNA levels are elevated in four unselected kidney adenocarcinoma cell lines that show a multidrug-resistant phenotype; and (2) multidrug resistance in these kidney cancer cell lines is reversed by verapamil and quinidine, agents known to reverse mdr1-associated drug resistance in cell lines selected for multidrug resistance in vitro. Quinidine 376-385 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 29806615-4 2018 Model cells were cultured on a membrane in the secretion component, and active transport mediated by P-glycoprotein (P-gp) was confirmed using the P-gp substrate rhodamine 123 with or without the P-gp inhibitor quinidine sulfate. Quinidine 211-228 ATP binding cassette subfamily B member 1 Homo sapiens 101-115 29806615-4 2018 Model cells were cultured on a membrane in the secretion component, and active transport mediated by P-glycoprotein (P-gp) was confirmed using the P-gp substrate rhodamine 123 with or without the P-gp inhibitor quinidine sulfate. Quinidine 211-228 ATP binding cassette subfamily B member 1 Homo sapiens 117-121